Invesco Ltd. Acquires 277,031 Shares of Amgen Inc. $AMGN

Invesco Ltd. lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 6.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,467,287 shares of the medical research company’s stock after purchasing an additional 277,031 shares during the period. Invesco Ltd.’s holdings in Amgen were worth $1,260,668,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. West Family Investments Inc. grew its holdings in Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 30 shares during the period. Viawealth LLC increased its position in Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after buying an additional 30 shares in the last quarter. LOM Asset Management Ltd raised its stake in shares of Amgen by 1.2% in the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after buying an additional 30 shares during the period. TAGStone Capital Inc. lifted its position in shares of Amgen by 0.8% during the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after buying an additional 32 shares in the last quarter. Finally, BBR Partners LLC lifted its position in shares of Amgen by 0.5% during the 3rd quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock valued at $2,008,000 after buying an additional 32 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several analyst reports. Citigroup increased their target price on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. The Goldman Sachs Group lifted their price target on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. BMO Capital Markets upped their price target on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Erste Group Bank raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Finally, Piper Sandler lifted their target price on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $354.00.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: MariTide and osteoporosis drug sales cited as a key driver of recent investor enthusiasm; analysts/coverage note product momentum that helped push earlier gains. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Operational/production support: Rapid Micro Biosystems reported that Amgen expanded a global Growth Direct system rollout (multi‑system order), signaling investments in manufacturing capacity and process efficiency. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Positive Sentiment: Institutional buying/positioning: Amgen is highlighted as a holding in a large income fund, reflecting demand from dividend/income managers seeking defensive, high‑yield large caps. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Macro/sector support: Prominent market commentators have endorsed large‑cap biotech as resilient growth plays, which supports longer‑term investor interest. Josh Brown: Biotech growth stocks immune to disruption risk
• Neutral Sentiment: Company presentation: A recent Leerink Global Healthcare conference transcript provides updated management commentary — useful for gauging near‑term guidance and pipeline cadence but not an immediate catalyst by itself. Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Valuation discussion: Coverage pieces assessing whether AMGN is mispriced highlight mixed returns vs. peers — useful context for investors but not a direct price mover. Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns
• Neutral Sentiment: Short‑interest data appears to contain errors (reports show zero shares/NaN changes and a 0.0 days-to-cover figure); there’s no clear evidence of meaningful short pressure at present.
• Negative Sentiment: Analyst stance: Jefferies initiated coverage with a Hold recommendation, which can cap momentum relative to a Buy/Outperform narrative and may contribute to near‑term selling pressure. Jefferies initiates coverage of Amgen (AMGN) with hold recommendation

Amgen Trading Down 2.6%

Shares of Amgen stock opened at $367.79 on Friday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The business has a 50-day moving average price of $356.96 and a 200-day moving average price of $324.63. The firm has a market cap of $198.26 billion, a price-to-earnings ratio of 25.85, a PEG ratio of 3.75 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.